Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nivolumab + telisotuzumab vedotin
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Nivolumab + telisotuzumab vedotin is an investigational combination therapy for cancer. Nivolumab is a fully human IgG4 monoclonal antibody that targets programmed cell death protein 1 (PD-1), acting as an immune checkpoint inhibitor to restore T-cell antitumor activity. Telisotuzumab vedotin (Teliso-V) is an antibody-drug conjugate composed of a monoclonal antibody targeting c-Met linked to the cytotoxic agent monomethyl auristatin E (MMAE). The combination aims to enhance antitumor efficacy by both directly killing c-Met–expressing tumor cells and boosting immune-mediated tumor cell destruction. This regimen has been studied in phase 1b clinical trials for patients with advanced non–small cell lung cancer (NSCLC) whose tumors overexpress c-Met[1][2][6].
- Brand names
- Opdivo (for nivolumab)Teliso-V (for telisotuzumab vedotin)
- Other names
- telisotuzumab vedotinABBV-399ABBV399ABBV 399ABT-399ABT399ABT 399telisotuzumab vedotin-tllvEmrelisTeliso-Vnivolumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on nivolumab + telisotuzumab vedotin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nivolumab + telisotuzumab vedotin.